BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8. [PMID: 17389705 DOI: 10.1136/gut.2006.107789] [Cited by in Crossref: 115] [Cited by in F6Publishing: 258] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Bizid S, Yacoub H, Mohamed G, Ben Slimane B, Boughoula K, Ben Abdallah H, Bouali R, Abedelli N. Does Anemia Have a Potential Effect on Type 2 Hepatorenal Syndrome? Can J Gastroenterol Hepatol 2020;2020:1134744. [PMID: 33381474 DOI: 10.1155/2020/1134744] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
3 Bittencourt PL, Terra C, Parise ER, Farias AQ, Arroyo V, Fernandez J, Pereira G, Maubouisson LM, Andrade GM, Costa FG, Codes L, Andrade AR, Mattos AA, Torres A, Couto F, Zyngier I. Intensive care management of patients with liver disease: proceedings of a single-topic conference sponsored by the Brazilian Society of Hepatology. Arq Gastroenterol 2015;52 Suppl 1:55-72. [PMID: 26959806 DOI: 10.1590/S0004-28032015000500004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Privette TW, Carlisle MC, Palma JK. Emergencies of the Liver, Gallbladder, and Pancreas. Emergency Medicine Clinics of North America 2011;29:293-317. [DOI: 10.1016/j.emc.2011.01.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
5 Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, Marot A, Spahr L, Demetter P, Sempoux C, Im GY, Saldarriaga J, Gustot T, Devière J, Thung SN, Minsart C, Sersté T, Bontempi G, Abdelrahman K, Henrion J, Degré D, Lucidi V, Rubbia-Brandt L, Nair VD, Moreno C, Deltenre P, Hoshida Y, Franchimont D. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology 2018;154:965-75. [PMID: 29158192 DOI: 10.1053/j.gastro.2017.10.048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
6 Kamimura H, Setsu T, Kimura N, Yokoo T, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M, Yamagiwa S, Terai S. Renal Impairment in Chronic Hepatitis B: A Review. Diseases. 2018;6. [PMID: 29921773 DOI: 10.3390/diseases6020052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
8 Katsounas A, Canbay A. Intensive Care Therapy for Patients with Advanced Liver Diseases. Visc Med 2018;34:283-9. [PMID: 30345286 DOI: 10.1159/000492088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clin Drug Investig 2019;39:45-54. [PMID: 30284699 DOI: 10.1007/s40261-018-0714-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
10 Koola JD, Chen G, Malin BA, Fabbri D, Siew ED, Ho SB, Patterson OV, Matheny ME. A clinical risk prediction model to identify patients with hepatorenal syndrome at hospital admission. Int J Clin Pract. 2019;73:e13393. [PMID: 31347754 DOI: 10.1111/ijcp.13393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Duah A, Duah F, Ampofo-boobi D, Addo BP, Osei-poku F, Agyei-nkansah A, Bellini MI. Acute Kidney Injury in Patients with Liver Cirrhosis: Prevalence, Predictors, and In-Hospital Mortality at a District Hospital in Ghana. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/4589767] [Reference Citation Analysis]
12 Wu I, Parikh CR. Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol 2008;3:1895-901. [PMID: 18922990 DOI: 10.2215/CJN.02030408] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
13 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol 2019;34:45-59. [PMID: 29497824 DOI: 10.1007/s00467-018-3893-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
15 Philips BJ, Lane K, Dixon J, Macphee I. The effects of acute renal failure on drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 2013;10:11-23. [DOI: 10.1517/17425255.2013.835802] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
16 Hengy B, Hayi-Slayman D, Page M, Christin F, Baillon JJ, Ber CE, Allaouchiche B, Rimmelé T. [Acute renal failure after acetaminophen poisoning: report of three cases]. Can J Anaesth 2009;56:770-4. [PMID: 19639374 DOI: 10.1007/s12630-009-9155-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
17 Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline vs terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol. 2018;37:424-429. [PMID: 30178092 DOI: 10.1007/s12664-018-0876-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
18 Zhou PQ, Zheng SP, Yu M, He SS, Weng ZH. Prognosis of acute-on-chronic liver failure patients treated with artificial liver support system. World J Gastroenterol 2015; 21(32): 9614-9622 [PMID: 26327769 DOI: 10.3748/wjg.v21.i32.9614] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
19 Sussman AN, Boyer TD. Management of refractory ascites and hepatorenal syndrome. Curr Gastroenterol Rep 2011;13:17-25. [PMID: 21080246 DOI: 10.1007/s11894-010-0156-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Rognant N. Acute kidney injury in patients with chronic liver disease. World J Hepatol 2015; 7(7): 993-1000 [PMID: 25954481 DOI: 10.4254/wjh.v7.i7.993] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
21 Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012;27:34-41. [PMID: 22287700 DOI: 10.1093/ndt/gfr736] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
22 Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2011; 17(29): 3448-3452 [PMID: 21876637 DOI: 10.3748/wjg.v17.i29.3448] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
23 Lehmann M, Bruns T, Herrmann A, Fritzenwanger M, Stallmach A. [54-year-old male with hepatic cirrhosis and therapy-associated torsade de pointes tachycardia]. Internist (Berl) 2011;52:445-8, 450. [PMID: 20938628 DOI: 10.1007/s00108-010-2667-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci. 2014;59:471-481. [PMID: 24146317 DOI: 10.1007/s10620-013-2899-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
25 Lata J. Hepatorenal syndrome. World J Gastroenterol 2012; 18(36): 4978-4984 [PMID: 23049205 DOI: 10.3748/wjg.v18.i36.4978] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
26 Tas A, Akbal E, Beyazit Y, Kocak E. Serum lactate level predict mortality in elderly patients with cirrhosis. Wien Klin Wochenschr. 2012;124:520-525. [PMID: 22810366 DOI: 10.1007/s00508-012-0208-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
27 Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e0431. [PMID: 29668606 DOI: 10.1097/md.0000000000010431] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
28 Fleming JN, Abou Abbass A. Hepatorenal syndrome: a comprehensive overview for the critical care nurse. Crit Care Nurs Clin North Am 2010;22:351-68. [PMID: 20691386 DOI: 10.1016/j.ccell.2010.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Kiser TH. Hepatorenal Syndrome. Int J Clin Med 2014;5:102-10. [PMID: 32284909 DOI: 10.4236/ijcm.2014.53018] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Suneja M, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011. Int J Nephrol 2016;2016:8419719. [PMID: 27144022 DOI: 10.1155/2016/8419719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Jia L, Xue R, Zhu Y, Zhao J, Li J, He WP, Wang XM, Duan ZH, Ren MX, Liu HX, Xing HC, Meng QH. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. BMC Med 2020;18:383. [PMID: 33287816 DOI: 10.1186/s12916-020-01814-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jun BG, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Lee YN, Kim SG, Kim YS, Cho YS, Lee SH, Kim HS. Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. J Korean Med Sci 2018;33:e99. [PMID: 29542304 DOI: 10.3346/jkms.2018.33.e99] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Stine JG, Wang J, Cornella SL, Behm BW, Henry Z, Shah NL, Caldwell SH, Northup PG. Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. Ann Hepatol 2018;17:300-6. [PMID: 29469046 DOI: 10.5604/01.3001.0010.8660] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
34 Rey R M, Delgado AF, De Zubiria A, Pinto R, De la Hoz-Valle JA, Pérez-Riveros ED, Ardila G, Sierra-Arango F. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia. PLoS One 2020;15:e0239834. [PMID: 33079947 DOI: 10.1371/journal.pone.0239834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver disease: Current and emerging indications. Journal of Gastroenterology and Hepatology 2018;33:591-8. [DOI: 10.1111/jgh.14009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
36 Huang HL, Nie X, He Y, Wu B, Song HL, Luo TX, Yang ZB, Gao BX, Li GX. Relationship between serum levels of endotoxin and PGI2/TXA2 and hepatorenal syndrome. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3132-3138 [DOI: 10.11569/wcjd.v21.i29.3132] [Reference Citation Analysis]
37 Heidemann J, Bartels C, Berssenbrügge C, Schmidt H, Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract. 2015;2015:457613. [PMID: 25983746 DOI: 10.1155/2015/457613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
38 Su CM, Chang WN, Tsai NW, Huang CR, Wang HC, Lu CH. Clinical features and outcome of community-acquired bacterial meningitis in adult patients with liver cirrhosis. Am J Med Sci 2010;340:452-6. [PMID: 20811273 DOI: 10.1097/MAJ.0b013e3181ee988d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011; 17(10): 1237-1248 [PMID: 21455322 DOI: 10.3748/wjg.v17.i10.1237] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
40 Khemichian S, Francoz C, Durand F, Karvellas CJ, Nadim MK. Hepatorenal Syndrome. Crit Care Clin 2021;37:321-34. [PMID: 33752858 DOI: 10.1016/j.ccc.2020.11.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Zhang E, Huang J, Wang K, Yu Q, Zhu C, Ren H. Pterostilbene Protects Against Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Failure by Upregulating the Nrf2 Pathway and Inhibiting NF-κB, MAPK, and NLRP3 Inflammasome Activation. J Med Food 2020;23:952-60. [PMID: 32701014 DOI: 10.1089/jmf.2019.4647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lee JW. Renal dysfunction in patients with chronic liver disease. Electrolyte Blood Press 2009;7:42-50. [PMID: 21468185 DOI: 10.5049/EBP.2009.7.2.42] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
43 Liu S, Wang X, Lu Y, Li T, Gong Z, Sheng T, Hu B, Peng Z, Sun X. The effects of intraoperative cryoprecipitate transfusion on acute renal failure following orthotropic liver transplantation. Hepatol Int 2013;7:901-9. [PMID: 26201928 DOI: 10.1007/s12072-013-9457-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
44 Riggio O, Nardelli S, Pasquale C, Pentassuglio I, Gioia S, Onori E, Frieri C, Salvatori FM, Merli M. No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Metab Brain Dis. 2016;31:1275-1281. [PMID: 26290375 DOI: 10.1007/s11011-015-9713-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
45 Gerbes A, Benesic A, Vogeser M, Krag A, Bendtsen F, Møller S. Serum Neutrophil Gelatinase-Associated Lipocalin – A Sensitive Novel Marker of Renal Impairment in Liver Cirrhosis? Digestion 2011;84:82-3. [DOI: 10.1159/000324881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
46 Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016;68:381-91. [PMID: 26994685 DOI: 10.1053/j.ajkd.2016.02.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
47 Shah N, Silva RG, Kowalski A, Desai C, Lerma E. Hepatorenal syndrome. Dis Mon. 2016;62:364-375. [PMID: 27372112 DOI: 10.1016/j.disamonth.2016.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
48 Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin vs other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532. [PMID: 28953318 DOI: 10.1002/14651858.cd011532.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
49 Cesari M, Frigo AC, Piano S, Angeli P. Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. Clin Exp Hepatol 2021;7:270-7. [PMID: 34712828 DOI: 10.5114/ceh.2021.108708] [Reference Citation Analysis]
50 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Gopi S, Mohta S, Saraya A. Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort. J Clin Exp Hepatol 2021;11:443-52. [PMID: 34276151 DOI: 10.1016/j.jceh.2020.11.001] [Reference Citation Analysis]
51 Zhao C, Dai CL. Role of Kupffer cells in hepatic fibrosis. Shijie Huaren Xiaohua Zazhi 2008; 16(26): 2959-2963 [DOI: 10.11569/wcjd.v16.i26.2959] [Reference Citation Analysis]
52 Assem M, Elsabaawy M, Abdelrashed M, Elemam S, Khodeer S, Hamed W, Abdelaziz A, El-Azab G. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10:377-385. [PMID: 26660707 DOI: 10.1007/s12072-015-9688-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
53 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
54 Low G, Owen NE, Joubert I, Patterson AJ, Graves MJ, Alexander GJ, Lomas DJ. Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites. Eur Radiol. 2015;25:2851-2858. [PMID: 25903705 DOI: 10.1007/s00330-015-3723-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
55 Gomes CGO, de Andrade MVM, Resende Guedes L, Carvalho Rocha H, Gardone Guimarães R, Castro Carvalho FA, Vilela EG. Clinical Aspects and Prognosis Evaluation of Cirrhotic Patients Hospitalized with Acute Kidney Injury. Can J Gastroenterol Hepatol 2019;2019:6567850. [PMID: 30941330 DOI: 10.1155/2019/6567850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
56 Seckin Y, Yigit A, Yesilada E, Gulbay G, Cagin YF, Gozukara H, Bılgıc Y, Yildirim O, Turkoz Y, Aksungur Z. Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome. Gastroenterol Res Pract 2016;2016:2579626. [PMID: 27594880 DOI: 10.1155/2016/2579626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
57 Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR; TRIBE-AKI Consortium. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013;57:753-62. [PMID: 22454364 DOI: 10.1002/hep.25735] [Cited by in Crossref: 225] [Cited by in F6Publishing: 201] [Article Influence: 25.0] [Reference Citation Analysis]
58 Allegretti AS, Ortiz G, Kalim S, Wibecan J, Zhang D, Shan HY, Xu D, Chung RT, Karumanchi SA, Thadhani RI. Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury. Dig Dis Sci 2016;61:3609-20. [PMID: 27655105 DOI: 10.1007/s10620-016-4316-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 2011; 17(18): 2273-2282 [PMID: 21633593 DOI: 10.3748/wjg.v17.i18.2273] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
60 Amin AA, Alabsawy EI, Jalan R, Davenport A. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Seminars in Nephrology 2019;39:17-30. [DOI: 10.1016/j.semnephrol.2018.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
61 Gupta K, Bhurwal A, Law C, Ventre S, Minacapelli CD, Kabaria S, Li Y, Tait C, Catalano C, Rustgi VK. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol 2021; 27(26): 3984-4003 [PMID: 34326609 DOI: 10.3748/wjg.v27.i26.3984] [Reference Citation Analysis]
62 Huang H, Lu Y, Zhou T, Gu G, Xia Q. Innate Immune Cells in Immune Tolerance After Liver Transplantation. Front Immunol. 2018;9:2401. [PMID: 30473690 DOI: 10.3389/fimmu.2018.02401] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
63 Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
64 Bernardi M. Spontaneous bacterial peritonitis: from pathophysiology to prevention. Intern Emerg Med. 2010;5 Suppl 1:S37-S44. [PMID: 20865473 DOI: 10.1007/s11739-010-0446-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
65 Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol 2015;15:167. [PMID: 26606982 DOI: 10.1186/s12876-015-0389-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
66 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
67 Chen YW, Chang CW, Chang CW, Wang TE, Wu CJ, Chen HH. Is an estimated glomerular filtration rate better than creatinine to be incorporated into the end-stage liver disease score? World J Hepatol 2012; 4(11): 291-298 [PMID: 23293714 DOI: 10.4254/wjh.v4.i11.291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Ćulafić Đ, Štulić M, Obrenović R, Miletić D, Mijač D, Stojković M, Jovanović M, Ćulafić M. Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis. World J Gastroenterol 2014; 20(21): 6573-6579 [PMID: 24914379 DOI: 10.3748/wjg.v20.i21.6573] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
69 Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfus 2013;11 Suppl 4:s18-25. [PMID: 24333308 DOI: 10.2450/2013.005s] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
70 Ou X, Mao S, Jiang Y, Zhang S, Ke C, Ma G, Cheng A, Wang M, Zhu D, Chen S, Jia R, Liu M, Sun K, Yang Q, Wu Y, Chen X. Viral-host interaction in kidney reveals strategies to escape host immunity and persistently shed virus to the urine. Oncotarget 2017;8:7336-49. [PMID: 28038465 DOI: 10.18632/oncotarget.14227] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
71 Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014; 20(10): 2555-2563 [PMID: 24627591 DOI: 10.3748/wjg.v20.i10.2555] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
72 Sobhonslidsuk A. Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome. World J Gastrointest Pharmacol Ther 2015; 6(3): 28-31 [PMID: 26261732 DOI: 10.4292/wjgpt.v6.i3.28] [Reference Citation Analysis]
73 Nickovic VP, Miric D, Kisic B, Kocic H, Stojanovic M, Buttice S, Kocic G. Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. Ren Fail 2018;40:340-9. [PMID: 29658815 DOI: 10.1080/0886022X.2018.1459699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Ibrahim ES, Alsebaey A, Zaghla H, Moawad Abdelmageed S, Gameel K, Abdelsameea E. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. Eur J Gastroenterol Hepatol 2017;29:1247-50. [PMID: 28902040 DOI: 10.1097/MEG.0000000000000967] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
75 Macedo E, Mehta RL. Prerenal failure: from old concepts to new paradigms. Curr Opin Crit Care 2009;15:467-73. [PMID: 19855270 DOI: 10.1097/MCC.0b013e328332f6e3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
76 Umgelter A, Wagner K, Reindl W, Nurtsch N, Huber W, Schmid RM. Haemodynamic effects of plasma-expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study. BMC Gastroenterol 2008;8:39. [PMID: 18752670 DOI: 10.1186/1471-230X-8-39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
77 Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol 2015;8:83-100. [PMID: 25729433 DOI: 10.1177/1756283X14564673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
78 Sanchez LO, Francoz C. Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis. United European Gastroenterol J 2021;9:220-8. [PMID: 33337286 DOI: 10.1177/2050640620980713] [Reference Citation Analysis]
79 Lei L, Li L, Zhang H. Advances in the Diagnosis and Treatment of Acute Kidney Injury in Cirrhosis Patients. Biomed Res Int 2017;2017:8523649. [PMID: 28573142 DOI: 10.1155/2017/8523649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Sarwar S, Khan AA. Hepatorenal syndrome:Response to terlipressin and albumin and its determinants. Pak J Med Sci 2016;32:274-8. [PMID: 27182222 DOI: 10.12669/pjms.322.9315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Shah AS, Amarapurkar DN. Natural History of Cirrhosis of Liver after First Decompensation: A Prospective Study in India. J Clin Exp Hepatol 2018;8:50-7. [PMID: 29743797 DOI: 10.1016/j.jceh.2017.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
82 Hung TH, Lay CJ, Tseng CW, Tsai CC, Tsai CC. The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study. PLoS One 2016;11:e0162987. [PMID: 27631098 DOI: 10.1371/journal.pone.0162987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
83 Gameiro J, Agapito Fonseca J, Monteiro Dias J, Melo MJ, Jorge S, Velosa J, Lopes JA. Prediction of acute kidney injury in cirrhotic patients: a new score combining renal, liver and inflammatory markers. Int J Nephrol Renovasc Dis 2018;11:149-54. [PMID: 29731657 DOI: 10.2147/IJNRD.S163602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
84 Lee HJ, Oh MJ. A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease. Clin Mol Hepatol 2013;19:179-84. [PMID: 23837143 DOI: 10.3350/cmh.2013.19.2.179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
85 Liu J, Shi Q, Xiao S, Zhou C, Zhou B, Yuan F, Zheng C, Lin S, Qian K, Feng G, Xiong B. Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage. J Gastroenterol Hepatol 2020;35:278-83. [PMID: 31222830 DOI: 10.1111/jgh.14761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
86 Karvellas CJ, Durand F, Nadim MK. Acute Kidney Injury in Cirrhosis. Critical Care Clinics 2015;31:737-50. [DOI: 10.1016/j.ccc.2015.06.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
87 Amini M, Runyon BA. Alcoholic hepatitis 2010: A clinician’s guide to diagnosis and therapy. World J Gastroenterol 2010; 16(39): 4905-4912 [PMID: 20954276 DOI: 10.3748/wjg.v16.i39.4905] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
88 Chaney A. A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis. Clin Exp Gastroenterol 2021;14:385-96. [PMID: 34675586 DOI: 10.2147/CEG.S323778] [Reference Citation Analysis]
89 Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, Christenson RH, Magder LS, Hutson WR, Seliger SL, Weir MR. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol 2014;39:543-52. [PMID: 24943131 DOI: 10.1159/000363584] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
90 Oberkofler CE, Dutkowski P, Stocker R, Schuepbach RA, Stover JF, Clavien PA, Béchir M. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Crit Care. 2010;14:R117. [PMID: 20550662 DOI: 10.1186/cc9068] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
91 Hung TH, Tseng CW, Tseng KC, Hsieh YH, Tsai CC, Tsai CC. Effect of renal function impairment on the mortality of cirrhotic patients with hepatic encephalopathy: a population-based 3-year follow-up study. Medicine (Baltimore) 2014;93:e79. [PMID: 25255022 DOI: 10.1097/MD.0000000000000079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
92 Low G, Alexander GJ, Lomas DJ. Renal impairment in cirrhosis unrelated to hepatorenal syndrome. Can J Gastroenterol Hepatol 2015;29:253-7. [PMID: 25874649 DOI: 10.1155/2015/967683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
93 Wong F, Blendis L. Historical Aspects of Ascites and the Hepatorenal Syndrome. Clin Liver Dis (Hoboken) 2021;18:14-27. [PMID: 34745581 DOI: 10.1002/cld.1090] [Reference Citation Analysis]
94 Park GC, Hwang S, Jung DH, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, Yoon YI, Cho HD, Kwon JH, Chung YK, Kang SH, Jung IJ, Choi JU, Lee SG. Is renal replacement therapy necessary in deceased donor liver transplantation candidates with hepatorenal syndrome?: a 2-year experience at a high-volume center. Ann Surg Treat Res 2020;98:102-9. [PMID: 32051819 DOI: 10.4174/astr.2020.98.2.102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
95 Urrunaga NH, Mindikoglu AL, Rockey DC. Renal dysfunction in cirrhosis. Curr Opin Gastroenterol 2015;31:215-23. [PMID: 25763790 DOI: 10.1097/MOG.0000000000000168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
96 Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI. Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clin J Am Soc Nephrol 2018;13:16-25. [PMID: 29122911 DOI: 10.2215/CJN.03610417] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 8.4] [Reference Citation Analysis]
97 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010;25:880-5. [PMID: 20074149 DOI: 10.1111/j.1440-1746.2009.06132.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
98 Thomson MJ, Taylor A, Sharma P, Lok AS, Tapper EB. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis. Dig Dis Sci 2020;65:1539-48. [PMID: 31571102 DOI: 10.1007/s10620-019-05858-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
99 Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I, Angelini ML, Moretti MI, Angeletti A, Piscaglia F, Manna GL. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol 2015; 4(5): 511-520 [PMID: 26558188 DOI: 10.5527/wjn.v4.i5.511] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
100 Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020; 26(40): 6111-6140 [PMID: 33177789 DOI: 10.3748/wjg.v26.i40.6111] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
101 Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013;11:1550-1558. [PMID: 23583467 DOI: 10.1016/j.cgh.2013.03.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
102 Velez JCQ. Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy. Kidney360 2022;3:382-95. [PMID: 35373127 DOI: 10.34067/KID.0006722021] [Reference Citation Analysis]
103 Oliver JB, Merchant AM, Koneru B. The Impact of Chronic Liver Disease on Postoperative Outcomes and Resource Utilization. J Invest Surg 2021;34:617-26. [PMID: 31661332 DOI: 10.1080/08941939.2019.1676846] [Reference Citation Analysis]
104 Mogawer MS, Nassef SAR, Elhamid SMA, Elkholy S, El Aziz NEA, Al-jarhi UM, Abdellatif AA. Role of renal Duplex ultrasonography in evaluation of hepatorenal syndrome. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00104-9] [Reference Citation Analysis]
105 Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
106 Pinchot JW, Kalva SP, Majdalany BS, Kim CY, Ahmed O, Asrani SK, Cash BD, Eldrup-Jorgensen J, Kendi AT, Scheidt MJ, Sella DM, Dill KE, Hohenwalter EJ; Expert Panels on Interventional Radiology and Vascular Imaging. ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension. J Am Coll Radiol 2021;18:S153-73. [PMID: 33958110 DOI: 10.1016/j.jacr.2021.02.013] [Reference Citation Analysis]
107 Kiamanesh D, Rumley J, Moitra VK. Monitoring and managing hepatic disease in anaesthesia. Br J Anaesth. 2013;111 Suppl 1:i50-i61. [PMID: 24335399 DOI: 10.1093/bja/aet378] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
108 Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol 2013;38:345-54. [PMID: 24107793 DOI: 10.1159/000355540] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
109 Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, Pattharanitima P, Petnak T, Lertjitbanjong P, Boonpheng B, Wijarnpreecha K, Zabala Genovez JL, Vallabhajosyula S, Jadlowiec CC, Qureshi F, Cheungpasitporn W. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample. World J Gastroenterol 2021; 27(45): 7831-7843 [PMID: 34963745 DOI: 10.3748/wjg.v27.i45.7831] [Reference Citation Analysis]
110 Kok B, Abraldes JG. Patient Selection in Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites and Associated Conditions. Curr Hepatology Rep 2019;18:197-205. [DOI: 10.1007/s11901-019-00470-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
111 Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care. 2012;16:211. [PMID: 22429536 DOI: 10.1186/cc11218] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
112 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Junuzovic D, Bijedic N, Sofic A, Bjelogrlic I, Mehmedovic A. Estimated Glomerular Filtration Rate (eGFR) Values as Predictor of Renal Insufficiency in Advanced Stages of Liver Diseases with Different Etiology. Med Arch 2014;68:159-62. [PMID: 25568524 DOI: 10.5455/medarh.2014.68.159-162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
113 Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J 2019;7:529-37. [PMID: 31065370 DOI: 10.1177/2050640619825719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Saxena R, Anand A, Deep A. Use of terlipressin in critically ill children with liver disease. BMC Nephrol 2020;21:360. [PMID: 32819297 DOI: 10.1186/s12882-020-01914-6] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Semin Intervent Radiol. 2015;32:445-454. [PMID: 26622108 DOI: 10.1055/s-0035-1564794] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
116 Huschak G, Kaisers U, Laudi S. Hepatorenales Syndrom. Anaesthesist 2013;62:571-82. [DOI: 10.1007/s00101-013-2197-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Zare Marzouni H, Davachi B, Rezazadeh M, Salehi Milani M, Matinfard S. Diagnostic Value of Hepatic Vein Ultrasound in Early Detection of Liver Cirrhosis. Galen Med J 2018;7:e1140. [PMID: 34466440 DOI: 10.22086/gmj.v0i0.1140] [Reference Citation Analysis]
118 Talasaz AH, Abbasi MR, Abkhiz S, Dashti-Khavidaki S. Tribulus terrestris-induced severe nephrotoxicity in a young healthy male. Nephrol Dial Transplant. 2010;25:3792-3793. [PMID: 20667992 DOI: 10.1093/ndt/gfq457] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
119 Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol 2015; 7(7): 926-941 [PMID: 25954476 DOI: 10.4254/wjh.v7.i7.926] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
120 Angeli P, Tonon M, Pilutti C, Morando F, Piano S. Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatol Int. 2016;10:115-123. [PMID: 26141259 DOI: 10.1007/s12072-015-9641-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
121 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 47.0] [Reference Citation Analysis]
122 Bloom RD, Bleicher M. Simultaneous liver-kidney transplantation in the MELD era. Adv Chronic Kidney Dis 2009;16:268-77. [PMID: 19576557 DOI: 10.1053/j.ackd.2009.05.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
123 Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol 2019; 25(28): 3684-3703 [PMID: 31391766 DOI: 10.3748/wjg.v25.i28.3684] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
124 Bittencourt PL, Farias AQ, Terra C. Renal failure in cirrhosis: Emerging concepts. World J Hepatol 2015; 7(21): 2336-2343 [PMID: 26413223 DOI: 10.4254/wjh.v7.i21.2336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
125 Caly WR, Abreu RM, Bitelman B, Carrilho FJ, Ono SK. Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo). 2017;72:405-410. [PMID: 28792999 DOI: 10.6061/clinics/2017(07)03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
126 Nevens F, Bittencourt PL, Coenraad MJ, Ding H, Hou MC, Laterre PF, Mendizabal M, Ortiz-Olvera NX, Vorobioff JD, Zhang W, Angeli P. Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Dig Dis Sci 2019;64:1419-31. [PMID: 30684079 DOI: 10.1007/s10620-018-5448-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
127 Mohamed MMG, Rauf A, Adam A, Kheiri B, Lacasse A, El-Halawany H. Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials. JGH Open 2021;5:896-901. [PMID: 34386597 DOI: 10.1002/jgh3.12600] [Reference Citation Analysis]
128 Altun R, Korkmaz M, Yıldırım E, Öcal S, Akbaş E, Selçuk H. Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response? Springerplus 2015;4:806. [PMID: 26722626 DOI: 10.1186/s40064-015-1625-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal Dysfunction in Cirrhosis: Critical Care Management. Indian J Crit Care Med 2021;25:207-14. [PMID: 33707901 DOI: 10.5005/jp-journals-10071-23721] [Reference Citation Analysis]
130 Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. World J Gastroenterol 2014; 20(42): 15499-15517 [PMID: 25400435 DOI: 10.3748/wjg.v20.i42.15499] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
131 Wang LN, Jiang HQ, Yang J, Wang YZ, Lv XP. Increased renal cell apoptosis and its mechanism in rats with biliary cirrhosis. Shijie Huaren Xiaohua Zazhi 2008; 16(24): 2702-2707 [DOI: 10.11569/wcjd.v16.i24.2702] [Reference Citation Analysis]
132 Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011;55:315-21. [PMID: 21167235 DOI: 10.1016/j.jhep.2010.11.020] [Cited by in Crossref: 137] [Cited by in F6Publishing: 121] [Article Influence: 11.4] [Reference Citation Analysis]
133 Al-Busafi SA, McNabb-Baltar J, Farag A, Hilzenrat N. Clinical manifestations of portal hypertension. Int J Hepatol. 2012;2012:203794. [PMID: 23024865 DOI: 10.1155/2012/203794] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
134 Caraceni P, Angeli P, Prati D, Bernardi M, Liumbruno GM, Bennardello F, Piccoli P, Velati C; Italian Association for the Study of the Liver (AISF)., Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus 2016;14:8-22. [PMID: 26820615 DOI: 10.2450/2016.0294-15] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
135 Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58:928-938. [PMID: 21962618 DOI: 10.1053/j.ajkd.2011.07.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
136 Utako P, Emyoo T, Anothaisintawee T, Yamashiki N, Thakkinstian A, Sobhonslidsuk A. Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. Biomed Res Int 2018;2018:5362810. [PMID: 29992152 DOI: 10.1155/2018/5362810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
137 Grünhage F, Heller J, Appenrodt B, Schmitz V, Sauerbruch T. [Medical therapy of complications in liver cirrhosis]. Internist (Berl) 2007;48:1349-57. [PMID: 17992496 DOI: 10.1007/s00108-007-1965-z] [Reference Citation Analysis]
138 Walayat S, Martin D, Patel J, Ahmed U, N Asghar M, Pai AU, Dhillon S. Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect. 2017;7:8-14. [PMID: 28634518 DOI: 10.1080/20009666.2017.1302704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
139 Yan X, Shao R, Wang Y, Mao X, Lei J, Zhang L, Zheng J, Liu A, Zhao H, Gao F, Wang J, Li P, Yao S, Xu M, Xu J, Liu D, Mi Y, Gong X, Ye J, Deng M, Dang T, Ji J, Shao C, Liu C, Gu Y, Wu Y, Wang F, Teng G, Li X, Qi X, Ju S, Qi X. Functional magnetic resonance imaging-based assessment of terlipressin vs. octreotide on renal function in cirrhotic patients with acute variceal bleeding (CHESS1903): study protocol of a multicenter randomized controlled trial. Ann Transl Med 2019;7:586. [PMID: 31807567 DOI: 10.21037/atm.2019.09.141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
140 Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol 2013; 5(12): 685-691 [PMID: 24432185 DOI: 10.4254/wjh.v5.i12.685] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
141 Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol. 2012;47:313-320. [PMID: 22038555 DOI: 10.1007/s00535-011-0485-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
142 Francoz C, Durand F. A new look at renal dysfunction in the cirrhotic patient. Crit Care. 2012;16:118. [PMID: 22385933 DOI: 10.1186/cc11207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
143 Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129:135-58. [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
144 Mattos AA, Wiltgen D, Jotz RF, Dornelles CMR, Fernandes MV, Mattos ÂZ. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis. Ann Hepatol 2020;19:451-7. [PMID: 32533951 DOI: 10.1016/j.aohep.2020.04.010] [Reference Citation Analysis]
145 Yoo J, Kim SW, Lee DH, Bae JS, Cho EJ. Prognostic role of spleen volume measurement using computed tomography in patients with compensated chronic liver disease from hepatitis B viral infection. Eur Radiol 2021;31:1432-42. [PMID: 32880698 DOI: 10.1007/s00330-020-07209-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Jeong JH, Park IS, Kim DH, Kim SC, Kang C, Lee SH, Kim TY, Lee SB. CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. Medicine (Baltimore). 2016;95:e3935. [PMID: 27367990 DOI: 10.1097/md.0000000000003935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
147 Hu J, Zhang X, Yu G, Cai H, Gu J, Hu M, Xiang D, Lian J, Yu L, Jia H, Zhang Y, Yang Y. Epstein-Barr virus infection is associated with a higher Child-Pugh score and may predict poor prognoses for patients with liver cirrhosis. BMC Gastroenterol 2019;19:94. [PMID: 31215410 DOI: 10.1186/s12876-019-1021-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
148 Garcovich M, Zocco MA, Gasbarrini A. Clinical use of albumin in hepatology. Blood Transfus 2009;7:268-77. [PMID: 20011638 DOI: 10.2450/2008.0080-08] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
149 Wong F, Boyer TD, Sanyal AJ, Pappas SC, Escalante S, Jamil K. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. Nephrol Dial Transplant. 2020;35:1554-1561. [PMID: 30887050 DOI: 10.1093/ndt/gfz048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
150 Umgelter A, Reindl W, Wagner KS, Franzen M, Stock K, Schmid RM, Huber W. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 2008;12:R4. [PMID: 18197961 DOI: 10.1186/cc6765] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
151 Gupta K, Rani P, Rohatgi A, Verma M, Handa S, Dalal K, Jain A. Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. Clin Exp Gastroenterol. 2018;11:317-324. [PMID: 30271187 DOI: 10.2147/ceg.s153858] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
152 Hunyady B, Jaroszewicz J, Lipták Ľ, Skladaný Ľ, Sperl J, Šváč J. Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland, Slovakia). Clin Exp Hepatol 2016;2:16-20. [PMID: 28856267 DOI: 10.5114/ceh.2016.58852] [Reference Citation Analysis]
153 Qasem AA, Farag SE, Hamed E, Emara M, Bihery A, Pasha H. Urinary biomarkers of acute kidney injury in patients with liver cirrhosis. ISRN Nephrol. 2014;2014:376795. [PMID: 24967242 DOI: 10.1155/2014/376795] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
154 Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 2012;61:1219-25. [PMID: 22661495 DOI: 10.1136/gutjnl-2012-302339] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
155 Klavan HL, Fortune BE. Elevated creatinine in a patient with cirrhosis. Clin Liver Dis (Hoboken) 2016;7:48-52. [PMID: 31041028 DOI: 10.1002/cld.534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Gleisner AL, Jung H, Lentine KL, Tuttle-Newhall J. Renal Dysfunction in Liver Transplant Candidates: Evaluation, Classification and Management in Contemporary Practice. J Nephrol Ther 2012;Suppl 4:006. [PMID: 32874772 DOI: 10.4172/2161-0959.S4-006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018;4:23. [PMID: 30213943 DOI: 10.1038/s41572-018-0022-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
158 Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009;15:2960-74. [PMID: 19554648 DOI: 10.3748/wjg.15.2960] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
159 Kwon HM, Moon YJ, Jung KW, Jeong HW, Park YS, Jun IG, Song JG, Hwang GS. Low Mean Arterial Blood Pressure is Independently Associated with Postoperative Acute Kidney Injury After Living Donor Liver Transplantation: A Propensity Score Weighing Analysis. Ann Transplant 2018;23:236-45. [PMID: 29632296 [PMID: 29632296 DOI: 10.12659/aot.908329] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
160 Tufoni M, Zaccherini G, Caraceni P, Bernardi M. Albumin: Indications in chronic liver disease. United European Gastroenterol J 2020;8:528-35. [PMID: 32213034 DOI: 10.1177/2050640620910339] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Tijera FHDL, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Herrera J, Pérez-Torres E, Abdo-Francis JM, Salas-Gordillo F, Pérez-Hernández JL. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol 2015; 21(16): 4975-4985 [PMID: 25945012 DOI: 10.3748/wjg.v21.i16.4975] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
162 Dzieżyc-Jaworska K, Litwin T, Członkowska A. Clinical manifestations of Wilson disease in organs other than the liver and brain. Ann Transl Med 2019;7:S62. [PMID: 31179299 DOI: 10.21037/atm.2019.03.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
163 Mirici-Cappa F, Caraceni P, Domenicali M, Gelonesi E, Benazzi B, Zaccherini G, Trevisani F, Puggioli C, Bernardi M. How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol 2011; 17(30): 3479-3486 [PMID: 21941414 DOI: 10.3748/wjg.v17.i30.3479] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
164 Heda R, Kovalic AJ, Satapathy SK. Peritransplant Renal Dysfunction in Liver Transplant Candidates. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.010] [Reference Citation Analysis]
165 Choi YJ, Kim JH, Koo JK, Lee CI, Lee JY, Yang JH, Ko SY, Choe WH, Kwon SY, Lee CH. Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal. Clin Mol Hepatol. 2014;20:185-191. [PMID: 25032185 DOI: 10.3350/cmh.2014.20.2.185] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
166 Sohn W, Ham CB, Kim NH, Kim HJ, Cho YK, Jeon WK, Kim BI. Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One 2020;15:e0243780. [PMID: 33315944 DOI: 10.1371/journal.pone.0243780] [Reference Citation Analysis]
167 Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Ther Clin Risk Manag. 2019;15:1383-1391. [PMID: 31819465 DOI: 10.2147/TCRM.S205328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
169 Hao JC, Wang WT, Yan LN, Li B, Wen TF, Yang JY, Xu MQ, Zhao JC, Wei YG. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol 2014; 20(32): 11356-11362 [PMID: 25170222 DOI: 10.3748/wjg.v20.i32.11356] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
170 Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol 2013; 5(5): 251-263 [PMID: 23717736 DOI: 10.4254/wjh.v5.i5.251] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
171 Furuya S, Chappell GA, Iwata Y, Uehara T, Kato Y, Kono H, Bataller R, Rusyn I. A mouse model of alcoholic liver fibrosis-associated acute kidney injury identifies key molecular pathways. Toxicol Appl Pharmacol 2016;310:129-39. [PMID: 27641628 DOI: 10.1016/j.taap.2016.09.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
172 Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia-Tsao G. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol 2012;10:1169-75. [PMID: 22801062 DOI: 10.1016/j.cgh.2012.06.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
173 Rochling FA, Zetterman RK. Management of Ascites: . Drugs 2009;69:1739-60. [DOI: 10.2165/11316390-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
174 Nayak SL, Maiwall R, Nandwani A, Ramanarayanan S, Mathur RP, Kumar R, Sarin SK, Vashishtha C. Management of acute kidney injury in cirrhosis. Hepatol Int 2013;7:813-9. [PMID: 26201918 DOI: 10.1007/s12072-013-9456-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Johnson TM, Overgard EB, Cohen AE, Dibaise JK. Nutrition Assessment and Management in Advanced Liver Disease. Nutr Clin Pract 2013;28:15-29. [DOI: 10.1177/0884533612469027] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
176 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
177 Acevedo J, Fernández J. New determinants of prognosis in bacterial infections in cirrhosis. World J Gastroenterol 2014; 20(23): 7252-7259 [PMID: 24966596 DOI: 10.3748/wjg.v20.i23.7252] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
178 Vincent JL, Russell JA, Jacob M, Martin G, Guidet B, Wernerman J, Ferrer R, McCluskey SA, Gattinoni L. Albumin administration in the acutely ill: what is new and where next? Crit Care 2014;18:231. [PMID: 25042164 DOI: 10.1186/cc13991] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 10.1] [Reference Citation Analysis]
179 Martin EF, Huang J, Xiang Q, Klein JP, Bajaj J, Saeian K. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl. 2012;18:914-929. [PMID: 22467623 DOI: 10.1002/lt.23440] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
180 El-Sheikh RM, Mansy SS, Nessim IG, Hosni HN, El Hindawi A, Hassanein MH, AbdelFattah AS. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS. 2019;127:93-105. [PMID: 30698308 DOI: 10.1111/apm.12917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
181 Russ KB, Stevens TM, Singal AK. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol. 2015;3:195-204. [PMID: 26623266 DOI: 10.14218/jcth.2015.00015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 6.1] [Reference Citation Analysis]
182 Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015;87:509-515. [PMID: 25296092 DOI: 10.1038/ki.2014.338] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
183 Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-radosavljevic M, Karner J, Karnel F, Reiberger T. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease 2017;49:1360-7. [DOI: 10.1016/j.dld.2017.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
184 Wong F. The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol. 2015;12:711-719. [PMID: 26484442 DOI: 10.1038/nrgastro.2015.174] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
185 Bunchorntavakul C, Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol 2012; 4(5): 158-168 [PMID: 22662285 DOI: 10.4254/wjh.v4.i5.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
186 Nie CY, Han T, Zhang L, Li Y, Liu H, Xiao SX, Li Y, Kang H, Liu SY. Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS. J Viral Hepat 2014;21:53-63. [PMID: 24329857 DOI: 10.1111/jvh.12122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
187 Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8. [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014] [Cited by in Crossref: 405] [Cited by in F6Publishing: 312] [Article Influence: 28.9] [Reference Citation Analysis]
188 Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.Nat Rev Nephrol. 2020;16:137-155. [PMID: 31723234 DOI: 10.1038/s41581-019-0218-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
189 Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011;7:517-26. [DOI: 10.1038/nrneph.2011.96] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
190 Regner KR, Singbartl K. Kidney Injury in Liver Disease. Crit Care Clin. 2016;32:343-355. [PMID: 27339675 DOI: 10.1016/j.ccc.2016.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
191 Guan Z, Ding Y, Liu Y, Zhang Y, Zhao J, Li C, Li Z, Meng S. Extracellular gp96 is a crucial mediator for driving immune hyperactivation and liver damage. Sci Rep 2020;10:12596. [PMID: 32724151 DOI: 10.1038/s41598-020-69517-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Sridharan K, Sivaramakrishnan G. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. J Gen Intern Med. 2018;33:97-102. [PMID: 28924736 DOI: 10.1007/s11606-017-4178-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
193 Mohapatra MK, Behera AK, Karua PC, Bariha PK, Rath A, Aggrawal KC, Nahak SR, Gudaganatti SS. Urinary bile casts in bile cast nephropathy secondary to severe falciparum malaria. Clin Kidney J 2016;9:644-8. [PMID: 27478612 DOI: 10.1093/ckj/sfw042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
194 Koola JD, Davis SE, Al-Nimri O, Parr SK, Fabbri D, Malin BA, Ho SB, Matheny ME. Development of an automated phenotyping algorithm for hepatorenal syndrome. J Biomed Inform 2018;80:87-95. [PMID: 29530803 DOI: 10.1016/j.jbi.2018.03.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
195 Velez JC, Kadian M, Taburyanskaya M, Bohm NM, Delay TA, Karakala N, Rockey DC, Nietert PJ, Goodwin AJ, Whelan TP. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron 2015;131:191-201. [PMID: 26485256 DOI: 10.1159/000441151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
196 Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in patients with cirrhosis--potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant. 2011;26:2735-2742. [PMID: 21690201 DOI: 10.1093/ndt/gfr354] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
197 Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: What is important for nephrologists and hepatologists. World J Gastroenterol 2010; 16(41): 5139-5147 [PMID: 21049548 DOI: 10.3748/wjg.v16.i41.5139] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
198 Wong F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol. 2016;22:415-422. [PMID: 27987536 DOI: 10.3350/cmh.2016.0056] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
199 Choi HM, Kim SC, Kim MG, Jo SK, Cho WY, Kim HK. Etiology and outcomes of anuria in acute kidney injury: a single center study. Kidney Res Clin Pract 2015;34:13-9. [PMID: 26484014 DOI: 10.1016/j.krcp.2014.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
200 Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci. 2012;57:210-214. [PMID: 21850494 DOI: 10.1007/s10620-011-1861-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
201 Shao ZY, Yan LN, Wang WT, Li B, Wen TF, Yang JY, Xu MQ, Zhao JC, Wei YG. Prophylaxis of chronic kidney disease after liver transplantation - experience from west China. World J Gastroenterol 2012; 18(9): 991-998 [PMID: 22408361 DOI: 10.3748/wjg.v18.i9.991] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
202 Klinzing S, Brandi G, Stehberger PA, Raptis DA, Béchir M. The combination of MELD score and ICG liver testing predicts length of stay in the ICU and hospital mortality in liver transplant recipients. BMC Anesthesiol. 2014;14:103. [PMID: 25844060 DOI: 10.1186/1471-2253-14-103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
203 Lang M, Lang AL, Tsui BQ, Wang W, Erly BK, Shen B, Kapoor B. Renal-function change after transjugular intra-hepatic portosystemic shunt placement and its relationship with survival: a single-center experience. Gastroenterol Rep (Oxf) 2021;9:306-12. [PMID: 34567562 DOI: 10.1093/gastro/goaa081] [Reference Citation Analysis]
204 Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol 2016; 8(6): 307-321 [PMID: 26962397 DOI: 10.4254/wjh.v8.i6.307] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 16.2] [Reference Citation Analysis]
205 Johnson KB, Mueller JL, Simon TG, Zheng H, King LY, Makar RS, Gervais DA, Chung RT. Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes. Dig Dis Sci 2015;60:2190-5. [PMID: 25724164 DOI: 10.1007/s10620-015-3578-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
206 Kerbert AJ, Verbeke L, Chiang FW, Laleman W, van der Reijden JJ, van Duijn W, Nevens F, Wolterbeek R, van Hoek B, Verspaget HW, Coenraad MJ. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. PLoS One 2015;10:e0138264. [PMID: 26378453 DOI: 10.1371/journal.pone.0138264] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
207 Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol. 2015;2015:108139. [PMID: 26266048 DOI: 10.1155/2015/108139] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
208 Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci. 2012;57:2362-2370. [PMID: 22562534 DOI: 10.1007/s10620-012-2180-x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
209 Sangroongruangsri S, Kittrongsiri K, Charatcharoenwitthaya P, Sobhonslidsuk A, Chaikledkaew U. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome. Clinicoecon Outcomes Res 2021;13:703-15. [PMID: 34349534 DOI: 10.2147/CEOR.S317390] [Reference Citation Analysis]
210 Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, Ansari N, Coca SG, Garcia-Tsao G, Parikh CR; TRIBE-AKI Consortium. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014;60:622-32. [PMID: 24375576 DOI: 10.1002/hep.26980] [Cited by in Crossref: 186] [Cited by in F6Publishing: 153] [Article Influence: 23.3] [Reference Citation Analysis]
211 Adachi T, Takeuchi Y, Takaki A, Oyama A, Wada N, Onishi H, Shiraha H, Okada H. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. Int J Mol Sci 2021;22:5582. [PMID: 34070416 DOI: 10.3390/ijms22115582] [Reference Citation Analysis]
212 Israelsen M, Dahl EK, Madsen BS, Wiese S, Bendtsen F, Møller S, Fialla AD, Jensen BL, Krag A. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. Am J Physiol Gastrointest Liver Physiol 2020;318:G313-21. [PMID: 31841026 DOI: 10.1152/ajpgi.00328.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
213 Tong X, Zhao F, Ren Y, Zhang Y, Cui Y, Wang Q. Injectable hydrogels based on glycyrrhizin, alginate, and calcium for three-dimensional cell culture in liver tissue engineering: Injectable hydrogels for liver tissue engineering. J Biomed Mater Res 2018;106:3292-302. [DOI: 10.1002/jbm.a.36528] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
214 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Reference Citation Analysis]
215 Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5(3): 156-168 [PMID: 25133044 DOI: 10.4292/wjgpt.v5.i3.156] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
216 Kakazu E, Kondo Y, Shimosegawa T. The Relationship between Renal Dysfunction and Abnormalities of the Immune System in Patients with Decompensated Cirrhosis. ISRN Gastroenterol 2012;2012:123826. [PMID: 23326675 DOI: 10.5402/2012/123826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
217 Dundar HZ, Yılmazlar T. Management of hepatorenal syndrome. World J Nephrol 2015; 4(2): 277-286 [PMID: 25949942 DOI: 10.5527/wjn.v4.i2.277] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
218 Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18(24): 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
219 Bozanich NK, Kwo PY. Renal Insufficiency in the Patient with Chronic Liver Disease. Clinics in Liver Disease 2015;19:45-56. [DOI: 10.1016/j.cld.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
220 Abdelhafez M, Nayfeh T, Atieh A, AbuShamma O, Babaa B, Baniowda M, Hrizat A, Hasan B, Hassett L, Hamadah A, Gharaibeh K. Diagnostic Performance of Fractional Excretion of Sodium for the Differential Diagnosis of Acute Kidney Injury: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2022:CJN. [PMID: 35545442 DOI: 10.2215/CJN.14561121] [Reference Citation Analysis]
221 Barakat AA, Nasr FM, Metwaly AA, El-Ghannam M. Systemic vascular resistance and fluid status in patients with decompensated liver cirrhosis with or without functional renal failure in Egypt. Electron Physician 2015;7:1174-82. [PMID: 26396731 DOI: 10.14661/2015.1174-1182] [Reference Citation Analysis]
222 Low G, Alexander GJ, Lomas DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract 2015;2015:207012. [PMID: 25649410 DOI: 10.1155/2015/207012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
223 Ahmed M, Ahmed S. Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones. Gastroenterology Res 2019;12:233-44. [PMID: 31636773 DOI: 10.14740/gr1219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
224 Wong F. Hepatorenal syndrome: current management. Curr Gastroenterol Rep 2008;10:22-9. [PMID: 18417039 DOI: 10.1007/s11894-008-0005-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
225 Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, Li C, Chen J, Xin SJ. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol 2013; 19(48): 9432-9438 [PMID: 24409073 DOI: 10.3748/wjg.v19.i48.9432] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
226 Davenport A. AKI in a patient with cirrhosis and ascites. Clin J Am Soc Nephrol. 2012;7:2041-2048. [PMID: 22977213 DOI: 10.2215/cjn.03390412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
227 Ahmed QA, El Sayed FS, Emad H, Mohamed E, Ahmed B, Heba P. Urinary biomarkers of acute kidney injury in patients with liver cirrhosis. Med Arch 2014;68:132-6. [PMID: 24937940 DOI: 10.5455/medarh.2014.68.132-136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
228 Sheng JQ, Hu PJ, Liu X, Huang TS, Chen YH. Predictive Analytics for Care and Management of Patients With Acute Diseases: Deep Learning-Based Method to Predict Crucial Complication Phenotypes. J Med Internet Res 2021;23:e18372. [PMID: 33576744 DOI: 10.2196/18372] [Reference Citation Analysis]
229 Mattos AA, Costabeber AM, Lionço LC, Tovo CV. Multi-resistant bacteria in spontaneous bacterial peritonitis: A new step in management? World J Gastroenterol 2014; 20(39): 14079-14086 [PMID: 25339797 DOI: 10.3748/wjg.v20.i39.14079] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
230 Camboni-Schellenberg EL, Sinner B. [Anesthesia with liver failure]. Anaesthesist 2016;65:77-94. [PMID: 26727937 DOI: 10.1007/s00101-015-0094-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
231 Ripoll C, Bari K, Garcia-Tsao G. Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis. J Clin Gastroenterol 2015;49:613-9. [PMID: 25203362 DOI: 10.1097/MCG.0000000000000207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
232 Huang H, Lu X, Yang H, Xu Y, Sang X, Zhao H. Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review. Ann Transl Med 2019;7:795. [PMID: 32042811 DOI: 10.21037/atm.2019.11.99] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
233 Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr. 2013;125:200-219. [PMID: 23579878 DOI: 10.1007/s00508-013-0337-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
234 Fukazawa K, Lee HT. Updates on Hepato-Renal Syndrome. J Anesth Clin Res. 2013;4:352. [PMID: 24459604 DOI: 10.4172/2155-6148.1000352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
235 Luo Y, Xu Y, Li M, Xie Y, Gong G. A new multiparameter integrated MELD model for prognosis of HBV-related acute-on-chronic liver failure. Medicine (Baltimore) 2016;95:e4696. [PMID: 27559979 DOI: 10.1097/MD.0000000000004696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
236 Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405 [PMID: 25170228 DOI: 10.3748/wjg.v20.i32.11400] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
237 Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Reference Citation Analysis]
238 Habib S, Khan K, Hsu CH, Meister E, Rana A, Boyer T. Differential Simultaneous Liver and Kidney Transplant Benefit Based on Severity of Liver Damage at the Time of Transplantation. Gastroenterology Res 2017;10:106-15. [PMID: 28496531 DOI: 10.14740/gr803w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
239 Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol 2014;4:302-11. [PMID: 25755577 DOI: 10.1016/j.jceh.2014.08.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
240 Wong F. Treatment to improve acute kidney injury in cirrhosis. Curr Treat Options Gastroenterol 2015;13:235-48. [PMID: 25773606 DOI: 10.1007/s11938-015-0050-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
241 Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS;  ADQI Workgroup. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. [PMID: 22322077 DOI: 10.1186/cc11188] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 9.9] [Reference Citation Analysis]
242 Goldaracena N, Marquez M, Selzner N, Spetzler VN, Cattral MS, Greig PD, Lilly L, Mcgilvray ID, Levy GA, Ghanekar A, Renner EL, Grant DR, Selzner M. Living vs. Deceased Donor Liver Transplantation Provides Comparable Recovery of Renal Function in Patients With Hepatorenal Syndrome: A Matched Case-Control Study: Live Donor Liver Transplantation for HRS. American Journal of Transplantation 2014;14:2788-95. [DOI: 10.1111/ajt.12975] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
243 Tawfik AK, Helmy A, Yousef M, Abou-Saif S, Kobtan A, Asaad E, Abd-Elsalam S. Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications. Hepat Med 2018;10:87-93. [PMID: 30214326 DOI: 10.2147/HMER.S174267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
244 Shah NL, Banaei YP, Hojnowski KL, Cornella SL. Management options in decompensated cirrhosis. Hepat Med 2015;7:43-50. [PMID: 26203291 DOI: 10.2147/HMER.S62463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
245 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Mohta S, Shalimar, Saraya A. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol 2021;11:343-53. [PMID: 33994717 DOI: 10.1016/j.jceh.2020.08.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Zang H, Liu F, Liu H, You S, Zhu B, Wan Z, Xin S. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatol Int 2016;10:807-18. [DOI: 10.1007/s12072-016-9756-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
247 Ribeiro TC, Chebli JM, Kondo M, Gaburri PD, Chebli LA, Feldner AC. Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication? Ther Clin Risk Manag 2008;4:919-25. [PMID: 19209274 DOI: 10.2147/tcrm.s2688] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
248 Shirata C, Hasegawa K, Kokudo T, Yamashita S, Yamamoto S, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction. World J Surg. 2018;42:4054-4062. [PMID: 29947980 DOI: 10.1007/s00268-018-4698-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
249 Umgelter A, Reindl W, Schmid RM, Huber W. Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Med. 2008;34:390-391. [PMID: 17917713 DOI: 10.1007/s00134-007-0877-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
250 Peng Z, Gong X, Yang Y, Huang L, Zhang Q, Zhang P, Wan R, Zhang B. Hepatoprotective effect of quercetin against LPS/d-GalN induced acute liver injury in mice by inhibiting the IKK/NF-κB and MAPK signal pathways. Int Immunopharmacol 2017;52:281-9. [PMID: 28963941 DOI: 10.1016/j.intimp.2017.09.022] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 10.2] [Reference Citation Analysis]
251 Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127-137. [PMID: 28533910 DOI: 10.1093/gastro/gox009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
252 Kamimura H, Watanabe T, Sugano T, Nakajima N, Yokoyama J, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Kato T, Watanabe G, Yamagiwa S, Terai S. A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion. Am J Case Rep 2017;18:1000-4. [PMID: 28919595 DOI: 10.12659/ajcr.904663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
253 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
254 Patidar KR, Sydnor M, Sanyal AJ. Transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2014;18:853-76. [PMID: 25438287 DOI: 10.1016/j.cld.2014.07.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
255 Nayak SL, Kumar M, Bihari C, Rastogi A. Bile Cast Nephropathy in Patients with Acute Kidney Injury Due to Hepatorenal Syndrome: A Postmortem Kidney Biopsy Study. J Clin Transl Hepatol. 2017;5:92-100. [PMID: 28660146 DOI: 10.14218/jcth.2016.00063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
256 Arab JP, Claro JC, Arancibia JP, Contreras J, Gómez F, Muñoz C, Nazal L, Roessler E, Wolff R, Arrese M, Benítez C. Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol 2016; 8(25): 1075-1086 [PMID: 27660674 DOI: 10.4254/wjh.v8.i25.1075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
257 Kim JW. [Type 2 hepatorenal syndrome in a cirrhotic patient who underwent gastric cancer surgery]. Korean J Gastroenterol 2010;56:125-7. [PMID: 20847602 DOI: 10.4166/kjg.2010.56.3.125] [Reference Citation Analysis]
258 Treeprasertsuk S, Wongkarnjana A, Jaruvongvanich V, Sallapant S, Tiranathanagul K, Komolmit P, Tangkijvanich P. Urine neutrophil gelatinase-associated lipocalin: a diagnostic and prognostic marker for acute kidney injury (AKI) in hospitalized cirrhotic patients with AKI-prone conditions. BMC Gastroenterol 2015;15:140. [PMID: 26474856 DOI: 10.1186/s12876-015-0372-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
259 Badawy AA, Zaher TI, Sharaf SM, Emara MH, Shaheen NE, Aly TF. Effect of alternative antibiotics in treatment of cefotaxime resistant spontaneous bacterial peritonitis. World J Gastroenterol 2013; 19(8): 1271-1277 [PMID: 23483064 DOI: 10.3748/wjg.v19.i8.1271] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
260 Matloff RG, Arnon R. The Kidney in Pediatric Liver Disease. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0457-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
261 Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol 2018;16:162-177.e1. [PMID: 28602971 DOI: 10.1016/j.cgh.2017.05.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
262 Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014;9:e107466. [PMID: 25203311 DOI: 10.1371/journal.pone.0107466] [Cited by in Crossref: 84] [Cited by in F6Publishing: 62] [Article Influence: 10.5] [Reference Citation Analysis]
263 Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, Ansari N, Lim J, Coca SG, Parikh CR; TRIBE-AKI Consortium. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol 2014;9:1857-67. [PMID: 25183658 DOI: 10.2215/CJN.09430913] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
264 Molinari M, Fernandez-Carrillo C, Dai D, Dana J, Clemente-Sanchez A, Dharmayan S, Kaltenmeier C, Liu H, Behari J, Rachakonda V, Ganesh S, Hughes C, Tevar A, Al Harakeh H, Emmanuel B, Humar A, Bataller R. Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis. Transpl Int 2021;34:1105-22. [PMID: 33780554 DOI: 10.1111/tri.13873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Angeloni S, Leboffe C, Parente A, Venditti M, Giordano A, Merli M, Riggio O. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol 2008; 14(17): 2757-2762 [PMID: 18461661 DOI: 10.3748/wjg.14.2757] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
266 Kim HR, Lee YS, Yim HJ, Lee HJ, Ryu JY, Lee HJ, Yoon EL, Lee SJ, Hyun JJ, Jung SW, Koo JS, Choung RS, Lee SW, Choi JH. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome. Clin Mol Hepatol 2013;19:417-20. [PMID: 24459647 DOI: 10.3350/cmh.2013.19.4.417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
267 Srivastava S, Shalimar S, Prakash S, Sharma H, Thakur B, Acharya SK. Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome. J Clin Exp Hepatol. 2015;5:276-285. [PMID: 26900268 DOI: 10.1016/j.jceh.2015.08.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
268 Mukhtar A, Dabbous H. Modulation of splanchnic circulation: Role in perioperative management of liver transplant patients. World J Gastroenterol 2016; 22(4): 1582-1592 [PMID: 26819524 DOI: 10.3748/wjg.v22.i4.1582] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
269 Ibrahim ES, Sharawy A. Effectiveness of intravenous infusion of N-acetylcysteine in cirrhotic patients undergoing major abdominal surgeries. Saudi J Anaesth 2015;9:272-8. [PMID: 26240545 DOI: 10.4103/1658-354X.154706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
270 Chiang CW, Lin YJ, Huang YB. Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome. Am J Case Rep 2019;20:5-9. [PMID: 30600312 DOI: 10.12659/AJCR.913150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
271 Wong F, O'Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, Thacker LR, Bajaj JS;  North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145: 1280-8. e1. [PMID: 23999172 DOI: 10.1053/j.gastro.2013.08.051] [Cited by in Crossref: 150] [Cited by in F6Publishing: 133] [Article Influence: 16.7] [Reference Citation Analysis]
272 Afinogenova Y, Tapper EB. The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. Gastroenterol Rep (Oxf). 2015;3:216-221. [PMID: 26178624 DOI: 10.1093/gastro/gov032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
273 Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst Rev 2017;6:CD005162. [PMID: 29943803 DOI: 10.1002/14651858.CD005162.pub4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
274 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
275 Wang X, Sarin SK, Ning Q. Definition of ACLF and inclusion criteria for extra-hepatic organ failure. Hepatol Int 2015;9:360-5. [PMID: 26016465 DOI: 10.1007/s12072-015-9637-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
276 Boldt J. [Guidelines on therapy with blood components and plasma derivatives: human albumin. Recommendations of the scientific advisory board of the Medical Council]. Anaesthesist 2010;59:566-74. [PMID: 20490440 DOI: 10.1007/s00101-010-1734-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
277 Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Fallon MB, Biggins SW, Subramanian RM, Thuluvath PJ, Kamath PS, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj JS. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. Am J Gastroenterol 2017;112:1103-10. [PMID: 28440305 DOI: 10.1038/ajg.2017.122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
278 Schmidt ML, Barritt AS, Orman ES, Hayashi PH. Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology. 2015;148:967-977.e2. [PMID: 25623044 DOI: 10.1053/j.gastro.2015.01.032] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 11.6] [Reference Citation Analysis]
279 Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45:1390-1402. [PMID: 28370090 DOI: 10.1111/apt.14052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
280 Gazzera C, Righi D, Valle F, Ottobrelli A, Grosso M, Gandini G. Fifteen years' experience with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents: retrospective review of clinical and technical aspects. Radiol Med 2009;114:83-94. [PMID: 19082786 DOI: 10.1007/s11547-008-0349-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
281 Gao YZ, Zhao LF, Ma J, Xue WH, Zhao H. Protective mechanisms of wogonoside against Lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. Eur J Pharmacol 2016;780:8-15. [PMID: 26921756 DOI: 10.1016/j.ejphar.2016.02.040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
282 Mocarzel LO, Bicca J, Jarske L, Oliveira T, Lanzieri P, Gismondi R, Ribeiro ML. Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. Case Rep Gastroenterol 2016;10:531-7. [PMID: 27843430 DOI: 10.1159/000448885] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
283 Wang L, Long Y, Li KX, Xu GS. Pharmacological treatment of hepatorenal syndrome: a network meta-analysis.Gastroenterol Rep (Oxf). 2020;8:111-118. [PMID: 32280470 DOI: 10.1093/gastro/goz043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol 2012;9:382-91. [DOI: 10.1038/nrgastro.2012.96] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 6.9] [Reference Citation Analysis]
285 Tariq R, Singal AK. Management of Hepatorenal Syndrome: A Review. J Clin Transl Hepatol 2020;8:192-9. [PMID: 32832400 DOI: 10.14218/JCTH.2020.00011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
286 Vicco MH, Rodeles L, Ferini F, Long AK, Musacchio HM. In-hospital mortality risk factors in patients with ascites due to cirrhosis. Rev Assoc Med Bras (1992) 2015;61:35-9. [PMID: 25909206 DOI: 10.1590/1806-9282.61.01.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]